Alnylam European Patent Upheld by Opposition Board
July 16, 2009
Alnylam European Patent Upheld by Opposition Board
The patent includes claims covering methods of silencing about 130 genes using siRNAs of up to 49 nucleotides in length and had been challenged by Merck subsidiary Sirna Therapeutics, according to Alnylam.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.